Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

tafasitamab-cxix

View Patient Information
An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Tafasitamab-cxix targets and binds to CD19, thereby depleting and eliminating CD19-expressing B cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
Synonym:immunoglobulin, anti-(human Cd19 antigen) (human-mus musculus monoclonal MOR00208 heavy chain), disulfide with human-mus musculus monoclonal MOR00208 .kappa.-chain, dimer
tafasitamab
US brand name:Monjuvi
Code name:MOR-00208
MOR00208
MOR208
XmAb5574
Search NCI's Drug Dictionary